Affluent Partners (HKG:1466) unit Beijing Baijin Biotechnology entered into a strategic cooperation framework agreement with Taihe Huamei (Zhejiang) Medical Technology to develop a new medicine in Mainland China, a Monday bourse filing said.
The new medicine, KMHH-03, which has been developed by Taihe Huamei (Zhejiang) Medical Technology, has obtained preliminary approval from China's National Medical Products Administration and is currently undergoing first-stage clinical research.
Under the contract, Beijing Baijin Biotechnology will invest in Taihe Huamei (Zhejiang) Medical Technology by subscribing for equity interest in the latter.
The parties are yet to decide the time and value of the investment under the contract, which will expire Dec. 31, 2027.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。